Purpose: The purpose of this study was to evaluate the utility of transcatheter thrombolytic therapy in 20 patients with acute or subacute (symptoms <40 days) portal and/or mesenteric vein thrombosis with severe symptoms, deteriorating clinical condition, and/or persistent symptoms despite anticoagulation.
Materials And Methods: This retrospective study examined 12 male patients and eight female patients seen over a period of 11 years. The average age was 37.6 years. Four of the patients had previously undergone liver transplantation. An anatomic classification system was established to describe the extent of thrombus at the time of diagnosis. Patients were treated with thrombolytic therapy via the transhepatic route, common femoral vein route, and/or superior mesenteric artery route. Improvement in symptoms, avoidance of bowel resection, complications, and radiographic evidence of clot resolution were the main clinical outcomes.
Results: Fifteen of the 20 patients exhibited some degree of lysis of the thrombus. Three patients had complete resolution, 12 had partial resolution, and five had no resolution. Eighty-five percent of patients (n = 17) had resolution of symptoms. Sixty percent of patients (n = 12) developed a major complication. No patients required bowel resection after thrombolytic therapy. One patient died with gastrointestinal hemorrhage and septic shock 2 weeks after thrombolytic therapy. Other major complications included bleeding and conditions requiring transfusion. No patients developed new portal or mesenteric thromboses. Two of the patients who received transplants eventually required repeat transplantation.
Conclusions: Transcatheter thrombolysis was beneficial in avoiding patient death, resolving thrombus, improving symptoms, and avoiding bowel resection. However, there was a high complication rate, indicating that this therapy should be reserved for patients with severe disease. Further evaluation of these techniques and outcomes should continue to be pursued.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.RVI.0000156265.79960.86 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Italian Society of Interventional Cardiology (SICI-GISE) Position paper: Integrated management and transcatheter interventions for acute pulmonary embolism].
G Ital Cardiol (Rome)
November 2024
U.O. Cardiologia, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna.
Pulmonary embolism (PE) is commonly treated primarily with pharmacological therapy, while advanced reperfusion therapies (transcatheter or surgical) are considered only in cases of contraindications or failure of standard therapies. Treatment algorithms vary depending on the patient's risk, with patients at intermediate or high risk potentially requiring evaluation for such advanced reperfusion therapies. Critical scenarios, such as contraindications to systemic thrombolysis or failure of pharmacological protocols, necessitate the activation of a multidisciplinary pulmonary embolism response team (PERT) and prompt therapeutic escalation.
View Article and Find Full Text PDFTrends in Transcatheter Mechanical Thrombectomy for Management of Acute Pulmonary Embolism.
Circ Cardiovasc Qual Outcomes
November 2024
Division of Cardiovascular Disease, Lifespan Cardiovascular Institute, Warren Alpert Medical School of Brown University, Providence, RI (A.E., O.H., M.S., S.T.M., P.A.S., J.D.A.).
Prospective study on the impact of different antithrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves-The NOTION-4 trial.
Am Heart J
January 2025
The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address:
Background: Transcatheter aortic valve replacement (TAVR) has become the standard-of-care treatment for a majority of patients with severe, symptomatic aortic stenosis. The postprocedural antithrombotic therapeutic management is still a topic of debate and could affect the incidence of HALT, a phenomenon which can be assessed by 4-dimensional computed tomography (4DCT).
Trial Design: The NOTION-4 trial is a randomized controlled trial comprising TAVR patients with no indication for oral anticoagulant (OAC) therapy, comparing lifelong single antiplatelet therapy (standard arm) versus early 3-month direct oral anticoagulant (DOAC) therapy followed by single antiplateletet therapy (experimental arm).
Cerebral Embolic Protection: Is There a Benefit for Left Atrial and Mitral Valve Procedures?
Curr Cardiol Rep
December 2024
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, J2-3, Cleveland, OH, 44195, USA.
Purpose Of Review: This review aims to highlight the current evidence on the use of cerebral embolic protection devices (CEPD) in left atrial and transcatheter mitral valve procedures. It also aims to summarize the antithrombotic management of patients undergoing such procedures.
Recent Findings: Ischemic stroke is one of the most devastating complications of structural heart procedures.
The impact of stroke and bleeding on mortality and quality of life during the first year after TAVI: A POPular TAVI subanalysis.
Catheter Cardiovasc Interv
November 2024
Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Article Synopsis
- Major or life-threatening bleeding and stroke are complications that can occur after transcatheter aortic valve implantation (TAVI), impacting both mortality and quality of life (QoL).
- Major bleeding increases the risk of death significantly, while minor bleeding does not affect mortality; however, both types of bleeding and stroke lead to lower mental QoL scores.
- The study highlights that monitoring these complications is essential, as they correlate with poorer mental well-being in patients during the first year post-TAVI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!